a tissue microarray consisting of melanoma and nevi cohorts Search Results


renal tissue microarray (tma  (BioChain Institute)
90
BioChain Institute renal tissue microarray (tma
Renal Tissue Microarray (Tma, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/Frozen+Tissue+Array+-+Dog+Male+Adult+Normal+Tissue%2C+Multi-tissue+I/pmc04693247-68-6-11
Average 90 stars, based on 1 article reviews
renal tissue microarray (tma - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
paraffin-embedded colorectal tissue microarray (tma  (Indivumed gmbh)
90
Indivumed gmbh paraffin-embedded colorectal tissue microarray (tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Paraffin Embedded Colorectal Tissue Microarray (Tma, supplied by Indivumed gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/paraffin+embedded+colorectal+tissue+microarray++tma/pmc06522288-179-22-26
Average 90 stars, based on 1 article reviews
paraffin-embedded colorectal tissue microarray (tma - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
semiautomatic tissue microarrayer tissue arrayer 1  (Beecher Instruments Inc)
90
Beecher Instruments Inc semiautomatic tissue microarrayer tissue arrayer 1
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Semiautomatic Tissue Microarrayer Tissue Arrayer 1, supplied by Beecher Instruments Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/semiautomatic+tissue+microarrayer+tissue+arrayer+1/pmc06636725-126-7-13
Average 90 stars, based on 1 article reviews
semiautomatic tissue microarrayer tissue arrayer 1 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tissue microarrayer quick-ray  (Unitma Co Ltd)
90
Unitma Co Ltd tissue microarrayer quick-ray
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tissue Microarrayer Quick Ray, supplied by Unitma Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/tissue+microarray+system+quick+ray+ut06/pmc09167936-103-18-23
Average 90 stars, based on 1 article reviews
tissue microarrayer quick-ray - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
human melanoma tissue microarray tma  (Novus Biologicals)
94
Novus Biologicals human melanoma tissue microarray tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Human Melanoma Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/Human+Various+Tissue+MicroArray+(Cancer)/pmc03887365-85-1-24
Average 94 stars, based on 1 article reviews
human melanoma tissue microarray tma - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
adult normal tissue ffpe tma  (Novus Biologicals)
94
Novus Biologicals adult normal tissue ffpe tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Adult Normal Tissue Ffpe Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/Human+Multi-tissue+Tissue+MicroArray+(Normal)/bio_rxiv__2024__12__11__627962-350-34-40
Average 94 stars, based on 1 article reviews
adult normal tissue ffpe tma - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
munich nine mile rsa493 b burgdorferi n a atcc strain 35210  (ATCC)
99
ATCC munich nine mile rsa493 b burgdorferi n a atcc strain 35210
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Munich Nine Mile Rsa493 B Burgdorferi N A Atcc Strain 35210, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/Borrelia+burgdorferi+Johnson+et+al%2E+emend%2E+Baranton+et+al/pm27814507-209-249-256
Average 99 stars, based on 1 article reviews
munich nine mile rsa493 b burgdorferi n a atcc strain 35210 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
tissue microarrayer instrument tma master 1.14 sp3  (3DHistech ltd)
90
3DHistech ltd tissue microarrayer instrument tma master 1.14 sp3
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tissue Microarrayer Instrument Tma Master 1.14 Sp3, supplied by 3DHistech ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/caseviewer+software/pmc09706716-106-28-35
Average 90 stars, based on 1 article reviews
tissue microarrayer instrument tma master 1.14 sp3 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tissue microarray  (US BIOLAB CORPORATION INC)
90
US BIOLAB CORPORATION INC tissue microarray
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tissue Microarray, supplied by US BIOLAB CORPORATION INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/tissue+microarray/pmc10689482-86-17-19
Average 90 stars, based on 1 article reviews
tissue microarray - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
onearray® microarray platform  (Phalanx Biotech)
90
Phalanx Biotech onearray® microarray platform
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Onearray® Microarray Platform, supplied by Phalanx Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/onearray++microarray+platform/us09676850-2063-24-27
Average 90 stars, based on 1 article reviews
onearray® microarray platform - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tissuescanhumannormal cdna array  (OriGene)
94
OriGene tissuescanhumannormal cdna array
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tissuescanhumannormal Cdna Array, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/TissueScan%2C+Human+Normal+cDNA+Array/pm38682204-54-13-16
Average 94 stars, based on 1 article reviews
tissuescanhumannormal cdna array - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
multicancer tissue cdna array  (OriGene)
93
OriGene multicancer tissue cdna array
Figure 1 BVES expression is significantly downregulated, and it is mislocalized in human colon carcinoma. (A) A human BVES hydrolysis probe was used to perform qPCR on an Origene <t>cDNA</t> array (TissueScan Cancer Survey I). Ct values were normalized to β-actin and then presented as fold reduction from matched normal (N) (n = 3 per tissue type) and tumor (T) tissue (n = 9 per tissue type). ***P < 0.001, 2-tailed unpaired t test. (B) Analysis of the combined Moffit Cancer Center and Vanderbilt Medical Center colon tumor expression array data set (10, normal samples; 6, adenomas; 33, stage I; 76, stage 2; 82, stage 3; and 59, stage 4; for combined total of 250 CRC samples). For whisker plots, the bottom and top of the boxes are the 25th and 75th percentile, respectively (the lower and upper quartiles, respectively), and the band near the middle of the box is the 50th percentile (median). The whiskers extend to the most extreme data points, which are no more than 1.5 times the interquartile range from the box. *P = 0.04, ***P = 0.001, ****P = 0.0001. (C) Representative immunofluorescence images from normal colon or adenocarci- noma (original magnification, ×400) of H&E, BVES (green), ZO-1 (red), DAPI (blue), and merged images.
Multicancer Tissue Cdna Array, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+tissue+microarray+consisting+of+melanoma+and+nevi+cohorts/TissueScan%2C+Cancer+Survey+cDNA+Array+96+-+I/10__1172_slash_jci44228-378-7-15
Average 93 stars, based on 1 article reviews
multicancer tissue cdna array - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


(A) Baseline expression of selected DDR markers was demonstrated and quantified in a colorectal tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue microarray cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

doi: 10.1158/1078-0432.CCR-18-2523

Figure Lengend Snippet: (A) Baseline expression of selected DDR markers was demonstrated and quantified in a colorectal tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue microarray cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.

Article Snippet: Baseline biological variability was established for each biomarker across 64 individual cores from 32 colorectal (CRC) tumor resections contained in a paraffin-embedded colorectal tissue microarray (TMA; Indivumed, Hamburg, Germany).

Techniques: Expressing, Microarray, Marker, Quantitation Assay, Derivative Assay

Representative H&E and immunofluorescence (IFA) images from 3 patients with advanced colorectal cancer enrolled in NCI trial NCT01851369 before and 5 days after start of treatment with a DNA damaging therapeutic regimen consisting of TCR102 plus temozolomide administered orally once daily. Red scale bar represents 10 μm.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

doi: 10.1158/1078-0432.CCR-18-2523

Figure Lengend Snippet: Representative H&E and immunofluorescence (IFA) images from 3 patients with advanced colorectal cancer enrolled in NCI trial NCT01851369 before and 5 days after start of treatment with a DNA damaging therapeutic regimen consisting of TCR102 plus temozolomide administered orally once daily. Red scale bar represents 10 μm.

Article Snippet: Baseline biological variability was established for each biomarker across 64 individual cores from 32 colorectal (CRC) tumor resections contained in a paraffin-embedded colorectal tissue microarray (TMA; Indivumed, Hamburg, Germany).

Techniques: Immunofluorescence

Figure 1 BVES expression is significantly downregulated, and it is mislocalized in human colon carcinoma. (A) A human BVES hydrolysis probe was used to perform qPCR on an Origene cDNA array (TissueScan Cancer Survey I). Ct values were normalized to β-actin and then presented as fold reduction from matched normal (N) (n = 3 per tissue type) and tumor (T) tissue (n = 9 per tissue type). ***P < 0.001, 2-tailed unpaired t test. (B) Analysis of the combined Moffit Cancer Center and Vanderbilt Medical Center colon tumor expression array data set (10, normal samples; 6, adenomas; 33, stage I; 76, stage 2; 82, stage 3; and 59, stage 4; for combined total of 250 CRC samples). For whisker plots, the bottom and top of the boxes are the 25th and 75th percentile, respectively (the lower and upper quartiles, respectively), and the band near the middle of the box is the 50th percentile (median). The whiskers extend to the most extreme data points, which are no more than 1.5 times the interquartile range from the box. *P = 0.04, ***P = 0.001, ****P = 0.0001. (C) Representative immunofluorescence images from normal colon or adenocarci- noma (original magnification, ×400) of H&E, BVES (green), ZO-1 (red), DAPI (blue), and merged images.

Journal: Journal of Clinical Investigation

Article Title: BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma

doi: 10.1172/jci44228

Figure Lengend Snippet: Figure 1 BVES expression is significantly downregulated, and it is mislocalized in human colon carcinoma. (A) A human BVES hydrolysis probe was used to perform qPCR on an Origene cDNA array (TissueScan Cancer Survey I). Ct values were normalized to β-actin and then presented as fold reduction from matched normal (N) (n = 3 per tissue type) and tumor (T) tissue (n = 9 per tissue type). ***P < 0.001, 2-tailed unpaired t test. (B) Analysis of the combined Moffit Cancer Center and Vanderbilt Medical Center colon tumor expression array data set (10, normal samples; 6, adenomas; 33, stage I; 76, stage 2; 82, stage 3; and 59, stage 4; for combined total of 250 CRC samples). For whisker plots, the bottom and top of the boxes are the 25th and 75th percentile, respectively (the lower and upper quartiles, respectively), and the band near the middle of the box is the 50th percentile (median). The whiskers extend to the most extreme data points, which are no more than 1.5 times the interquartile range from the box. *P = 0.04, ***P = 0.001, ****P = 0.0001. (C) Representative immunofluorescence images from normal colon or adenocarci- noma (original magnification, ×400) of H&E, BVES (green), ZO-1 (red), DAPI (blue), and merged images.

Article Snippet: BVES TaqMan qRT-PCR was performed on a multicancer tissue cDNA array (TissueScan Cancer Survey I, OriGene) according to the manufacturers protocol.

Techniques: Expressing, Whisker Assay, Immunofluorescence